Literature DB >> 7861550

Hypercalcemia and cosecretion of interleukin-6 and parathyroid hormone related peptide by a human renal cell carcinoma implanted into nude mice.

M Weissglas1, D Schamhart, C Löwik, S Papapoulos, P Vos, K H Kurth.   

Abstract

Humoral hypercalcemia of malignancy is a paraneoplastic syndrome believed to be due to production by the tumor of substances that stimulate osteoclastic bone resorption primarily. The human renal cell carcinoma cell line RC-8, grown in nude mice, was investigated for factors involved in renal cancer-induced hypercalcemia. At a tumor load of 200 to 400 mm.3 the mice developed hypercalcemia and hypophosphatemia associated with a rise in serum 1,25-dihydroxyvitamin D concentration and cachexia. The tumor released 1) significant amounts of human interleukin-6 (IL-6) and 2) parathyroid hormone-related peptide (PTHrP) into the circulation. Cancer cells further expressed mRNA for both human IL-6 and PTHrP. No secretion of human tumor necrosis factor-alpha or interleukin-1 beta could be demonstrated in the circulation of the host. Antibodies to IL-6 caused a significant (p = 0.043) inhibition of tumor growth and decreased serum calcium concentrations compared with control animals. Our data suggest that IL-6 is involved, either directly or indirectly, in the development of hypercalcemia in renal cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7861550

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  7 in total

Review 1.  Rare and changeable as a chameleon: paraneoplastic syndromes in renal cell carcinoma.

Authors:  M Hegemann; N Kroeger; A Stenzl; J Bedke
Journal:  World J Urol       Date:  2018-02-10       Impact factor: 4.226

Review 2.  [Paraneoplastic syndrome in renal cell carcinoma].

Authors:  J Bedke; S Buse; M Kurosch; A Haferkamp; D Jäger; M Hohenfellner
Journal:  Urologe A       Date:  2007-01       Impact factor: 0.639

3.  Cholangiocellular carcinoma that produced both granulocyte-colony-stimulating factor and parathyroid hormone-related protein.

Authors:  Tetsuro Sohda; Hiroshi Shiga; Hidetoshi Nakane; Hiroshi Watanabe; Morishige Takeshita; Shotaro Sakisaka
Journal:  Int J Clin Oncol       Date:  2006-06       Impact factor: 3.402

4.  Supportive therapy and complementary medicine in renal cell carcinoma.

Authors:  M Johannsen; C Stoll; M Raida; B van Oorschot; A Flörcken
Journal:  World J Urol       Date:  2021-11-25       Impact factor: 3.661

5.  A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer.

Authors:  J-F Rossi; S Négrier; N D James; I Kocak; R Hawkins; H Davis; U Prabhakar; X Qin; P Mulders; B Berns
Journal:  Br J Cancer       Date:  2010-08-31       Impact factor: 7.640

6.  Parathyroid hormone related protein and interleukin-6 mRNA expression in larynx and renal cell carcinomas from normocalcaemic and hypercalcaemic patients.

Authors:  D H Schweitzer; I L Boxman; C W Löwik; J H van Krieken; M G Weissglas; R J Baatenburg de Jong; S E Papapoulos
Journal:  J Clin Pathol       Date:  1995-10       Impact factor: 3.411

7.  Pancreatic Adenocarcinoma Producing Parathyroid Hormone-Related Protein.

Authors:  Reiko Yamada; Kyosuke Tanaka; Hiroyuki Inoue; Takashi Sakuno; Tetsuro Harada; Naohiko Yoshizawa; Hiroshi Miura; Toshihumi Takeuchi; Misaki Nakamura; Masaki Katsurahara; Yasuhiko Hamada; Noriyuki Horiki; Yoshiyuki Takei
Journal:  Case Rep Oncol Med       Date:  2017-08-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.